Relay Therapeutics officer proposes $169K stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. (RLAY) reports that Officer Donald Bergstrom gave notice of a proposed sale of 10,269 common shares, with an aggregate market value of $169,130.43 and an approximate sale date of November 18, 2026. The notice lists October 30, 2025 as the adoption date for a Rule 10b5-1 plan. Bergstrom's sales during the prior three months included 2,252 shares on October 28, 2026, for gross proceeds of $41,932.24, and 8,530 shares on September 8, 2026, for gross proceeds of $161,775.72; the latter is listed under 10b5-1 sales. The shares proposed for sale were acquired upon vesting of restricted stock units during June 26, 2022 through July 27, 2023.
Key Figures
Key Terms
10b5-1 regulatory
Restricted Stock Units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent stock sales did Donald Bergstrom report for RLAY?
AI-generated analysis. How Rhea-AI works. Not financial advice.